Page 13 - சீனா இணை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray Posted On: 2020-12-22 20:36:41 (Time Zone: Arizona, USA) Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercializing its innovative nasal spray Ryaltris™ across 33 countries in Europe, including the Balkan region. Ryaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.

South africaL vivs ka oblastYu hanSaudi arabia generalSaudi arabiaSouth koreaSachin guptaPio meiSeqirus ptyMenarini groupGlenmark pharmaceuticalsYuhan corporationEuropean unionLatam glenmark pharmaceuticalsHikma pharmaceuticalsGlenmark pharmaceuticals ltd